Stroke Prevention in Atrial Fibrillation

Published Online: Tuesday, January 14, 2014
Follow Pharmacy_Times:
For this podcast, produced by the American Society of Health-System Pharmacists, 3 pharmacists were interviewed on issues relating to preventing stroke in atrial fibrillation. The interviewees are: James Kalus, PharmD, senior manager of patient care services in the department of pharmacy at Henry Ford Hospital in Detroit; Cynthia Sanoski, PharmD, chair and associate professor in the department of pharmacy practice at Jefferson School of Pharmacy at Thomas Jefferson University in Philadelphia; and Nancy Shapiro, PharmD, clinical associate professor in the department of pharmacy practice at the University of Illinois at Chicago College of Pharmacy.
 
To listen to this podcast, click here.
Related Articles
The FDA’s Cardiovascular and Renal Drugs Advisory Committee has recommended the approval of edoxaban (Savaysa) for treating patients with nonvalvular atrial fibrillation, a type of arrhythmia that can potentially cause a stroke.
Leading groups fighting chronic disease argue that Congress intended for eligible consumers to receive tax credits that help make health coverage bought in either federal or state-run marketplaces more affordable.
Asthmatics with vitamin D deficiency are significantly more susceptible to acute asthma attacks.
New recommendations for the removal of protective gear highlight the need for enhanced technologies.
Latest Issues
$auto_registration$